Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir Ponomarev

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Cancer Letters|December 3, 2014
Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcomaVasilios Liapis, Agatha Labrinidis, Irene Zinonos, et al.
Anticancer Research|December 16, 2014
Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs)Irene Zinonos, Agatha Labrinidis, Vasilios Liapis, et al.
Nature Biomedical Engineering|July 3, 2023
Simultaneous quantitative imaging of two PET radiotracers via the detection of positron-electron annihilation and prompt gamma emissionsEdwin C Pratt, Alejandro Lopez-Montes, Alessia Volpe, et al.
Cancer Medicine|January 11, 2016
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine modelsVasilios Liapis, Irene Zinonos, Agatha Labrinidis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2018
Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered LymphocytesSimone Krebs, Afruja Ahad, Lukas M Carter, et al.
Blood Cancer Discovery|October 22, 2020
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple MyelomaCarlos Fernández de Larrea, Mette Staehr, Andrea V Lopez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myelomaAgatha Labrinidis, Peter Diamond, Sally Martin, et al.
Neurocritical Care|December 12, 2022
Characterization of Cerebral Hemodynamics with TCD in Patients Undergoing VA-ECMO and VV-ECMO: a Prospective Observational StudyGiorgio Caturegli, Lucy Q Zhang, Yunis Mayasi, et al.
Cancer Medicine|August 12, 2017
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcomaVasilios Liapis, Aneta Zysk, Mark DeNichilo, et al.
The American Journal of Pathology|October 23, 2016
Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor SignalingAmita Shukla-Dave, Mireia Castillo-Martin, Ming Chen, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Cancer Letters|December 3, 2014
Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcomaVasilios Liapis, Agatha Labrinidis, Irene Zinonos, et al.
Anticancer Research|December 16, 2014
Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs)Irene Zinonos, Agatha Labrinidis, Vasilios Liapis, et al.
Nature Biomedical Engineering|July 3, 2023
Simultaneous quantitative imaging of two PET radiotracers via the detection of positron-electron annihilation and prompt gamma emissionsEdwin C Pratt, Alejandro Lopez-Montes, Alessia Volpe, et al.
Cancer Medicine|January 11, 2016
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine modelsVasilios Liapis, Irene Zinonos, Agatha Labrinidis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2018
Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered LymphocytesSimone Krebs, Afruja Ahad, Lukas M Carter, et al.
Blood Cancer Discovery|October 22, 2020
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple MyelomaCarlos Fernández de Larrea, Mette Staehr, Andrea V Lopez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myelomaAgatha Labrinidis, Peter Diamond, Sally Martin, et al.
Neurocritical Care|December 12, 2022
Characterization of Cerebral Hemodynamics with TCD in Patients Undergoing VA-ECMO and VV-ECMO: a Prospective Observational StudyGiorgio Caturegli, Lucy Q Zhang, Yunis Mayasi, et al.
Cancer Medicine|August 12, 2017
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcomaVasilios Liapis, Aneta Zysk, Mark DeNichilo, et al.
The American Journal of Pathology|October 23, 2016
Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor SignalingAmita Shukla-Dave, Mireia Castillo-Martin, Ming Chen, et al.
Pageof 8